Tanezumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tanezumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetNGF
Clinical data
Other namesRN624
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6464H9942N1706O2026S46
Molar mass145445.32 g·mol−1
 ☒N☑Y (what is this?)  (verify)

Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain. Tanezumab was discovered and developed by Rinat Neuroscience[1] and was acquired by Pfizer in 2006.

In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).[2] Another Phase III trial for hip pain in OA[3] was halted in June 2010 when some patients needed hip replacement.[4]

Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.[5]

In March 2012, the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.[6][7]

A Phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.[8]

At February 19, 2019 the co-development partners - Eli Lilly and Pfizer - announced that treatment with tanezumab 10 mg met the primary endpoint, demonstrating a statistically significant improvement in chronic low back pain at 16 weeks compared to placebo (however, 5 mg arm demonstrated a numerical improvement in pain, but did not reach statistical significance compared to placebo at the week 16 analysis).[9]

See also[edit]

References[edit]

  1. ^ Shelton, D. L.; Zeller, J.; Ho, W. H.; Pons, J.; Rosenthal, A. (2005). "Anti-ngf antibodies and methods using same". Pain. 116 (1–2): 8–16. doi:10.1016/j.pain.2005.03.039. PMID 15927377.
  2. ^ "Tanezumab in Osteoarthritis of the Knee". 2009
  3. ^ "Tanezumab in Osteoarthritis Of The Hip".
  4. ^ [1][dead link]
  5. ^ "Phase II trials involving Tanezumab".
  6. ^ [2][dead link]
  7. ^ [3][dead link]
  8. ^ Brown, Mark T.; Murphy, Frederick T.; Radin, David M.; Davignon, Isabelle; Smith, Michael D.; West, Christine R. (Jul 2013). "Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial". Arthritis Rheum. 65 (7): 1795–803. doi:10.1002/art.37950. PMID 23553790.
  9. ^ "Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain". Seeking Alpha.

External links[edit]